FDA Drug Recalls

Recalls / Class III

Class IIID-0990-2019

Product

Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 42291-634-01) and b) 500 tablets (NDC 42291-634-50) bottles, Rx Only Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Brand name
Oxybutynin Chloride
Generic name
Oxybutynin Chloride
Active ingredient
Oxybutynin Chloride
Route
Oral
NDCs
42291-633, 42291-634, 42291-635
FDA application
ANDA078503
Affected lot / code info
Lots: a) 22738 Exp. 07/2020 and b) 22739 Exp. 07/2020

Why it was recalled

Failed Dissolution Specifications

Recalling firm

Firm
AVKARE Inc.
Manufacturer
AvKARE
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
615 N 1st St, N/A, Pulaski, Tennessee 38478-2403

Distribution

Quantity
a) 2947 and b) 3379
Distribution pattern
Nationwide.

Timeline

Recall initiated
2019-03-01
FDA classified
2019-03-11
Posted by FDA
2019-03-20
Terminated
2020-01-14
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0990-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Oxybutynin Chloride · FDA Drug Recalls